Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  BG ControlMedical DevicesInsulinGlucose MonitoringIssue 707

Insulin Pumps vs. Multiple Daily Injections (MDI): Which is Better?

Can insulin pumps reduce glycemic variability in type 1 diabetes?...

Advertisement

A new cross-sectional observational cohort study looked at continuous subcutaneous insulin infusion (CSII), aka insulin pump, versus multiple daily injections (MDI) to determine which insulin delivery system resulted in less blood glucose variability in type 1 pediatric diabetes patients. Large variations in blood glucose have been implicated in causing cardiovascular complications which can lead to a number of comorbidities and mortality in diabetics.

This recent study was performed in 48 pediatric type 1 diabetes patients, 22 of whom used an insulin pump while the others used MDI. The patients were followed for 3 days using continuous blood glucose monitoring; blood glucose variability was also assessed in 2 consecutive 24 hour periods by a surrogate marker, F2-isoprostanes and/or urinary prostaglandin F2 excretion. Results showed that standard deviation of mean glucose concentration (p<0.05) and insulin requirements, HDL-cholesterol, the mean of glycemic excursions (p<0.01) were statistically lower in the insulin pump group.

While the study did not specifically look at the impact of insulin pump use vs. MDI on cardiovascular complications, one could assume that limiting glucose variations would have a positive impact on the cardiovascular system. The study was small and the MDI groups were even smaller. Each MDI group had somewhere between 4 - 9 patients who were assigned certain insulins whether that be normal, fast acting, basal and/or a combo of thereof. Further research and longitudinal studies would be of benefit to better assess association of CSII therapy versus MDI therapy and their impact on cardiovascular, co-morbidity, and mortality outcomes.

Practice Pearls:

  • Large variations in plasma glucose have been implicated in causing cardiovascular complications.
  • Patients with type 1 diabetes are significantly more likely to develop cardiovascular disease versus their peers.
  • Using continuous subcutaneous insulin infusion seems to be associated with reduced variations in blood glucose levels versus using multiple daily injections in type 1 diabetes.

Schreiver, C. et al. Glycemic Variability in Pediatric Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion (CSII) or Multiple Daily Injections (MDI). Clin Endocrinol. 2013;79(5):641-647 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 12 December, 2013 and appeared in  BG ControlMedical DevicesInsulinGlucose MonitoringIssue 707

Past five issues: Issue 752 | SGLT-2 Inhibitors Special Edition October 2014 | Diabetes Clinical Mastery Series Issue 211 | Issue 751 | Humulin Insulin Special Edition October 2014 |

2014 Most Popular Articles:

FDA Approves Once-Weekly GLP-1 Diabetes Treatment Regimen for T2DM
Posted September 25, 2014
Two Positive Phase 3 Trials for ITCA 650, a GLP-1 Agonist, in Type 2 Diabetes
Posted October 10, 2014
Stanley Schwartz, MD: A New Way of Classifying Diabetes - The Beta-Cell Centric Approach
Posted September 29, 2014
Best Insulin Regimen for Type 1's
Posted October 10, 2014
EASD: Insulin Pumps Lower Mortality Rate 29% Compared to Multiple Injections in T1DM
Posted October 03, 2014
New GLP-1 Receptor Agonist as an Alternative to Insulin Glargine?
Posted October 10, 2014
Handbook of Diabetes, 4th Ed., Excerpt #13: Control and Complications
Posted October 13, 2014
Adding an SGLT2 to Insulin Improved Control
Posted October 17, 2014
Non-Caloric Artificial Sweeteners May Induce Glucose Intolerance
Posted October 10, 2014
GLP-1 Agonist Medications Chart
Posted September 23, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Are your patients getting enough glucose strips to manage their diabetes?


Advertisement


Search Articles On Diabetes In Control